Evaluation of the potential impact of ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics

mBio

Volumn 6, Issue 1, 2015, Pages

  Kugelman, Jeffrey R ^a   Sanchez Lockhart, Mariano ^a   Andersen, Kristian G ^b   Gire, Stephen ^b   Park, Daniel J ^b   Sealfon, Rachel ^c   Lin, Aaron E ^b   Wohl, Shirlee ^b   Sabeti, Pardis C ^b   Kuhn, Jens H ^d   Palacios, Gustavo F ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b HARVARD UNIVERSITY   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AVI 7537; AVI 7539; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 13C6; MONOCLONAL ANTIBODY 13F6; MONOCLONAL ANTIBODY 1H3; MONOCLONAL ANTIBODY 2G4; MONOCLONAL ANTIBODY 4G7; MONOCLONAL ANTIBODY 6D8; MORPHOLINO OLIGONUCLEOTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRAL PROTEIN;

AFRICA; ANTISENSE THERAPY; ARTICLE; BINDING AFFINITY; BINDING SITE; EBOLA VIRUS; EPIDEMIC; GENE MUTATION; GENE THERAPY; GENETIC DRIFT; GENETIC VARIABILITY; HUMAN; LETHALITY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SEQUENCE BASED THERAPY; VIRUS GENOME; VIRUS STRAIN; VIRUS TRANSMISSION; EBOLAVIRUS; GENETIC VARIATION; GENETICS; GENOMICS; HEMORRHAGIC FEVER, EBOLA; METABOLISM; MUTATION; VIROLOGY;

EBOLA VIRUS;

EBOLAVIRUS; GENETIC VARIATION; GENOMICS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MUTATION; RNA, SMALL INTERFERING; VIRAL PROTEINS;

EID: 84924146454     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02227-14     Document Type: Article

References (24)

1. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keita S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traore A, Kolie M, Malano ER, Heleze E, Bocquin A, Mely S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Gunther S. 2014. Emergence of Zaire Ebola virus disease in Guinea-preliminary report. N Engl J Med 371: 1418-1425. http://dx. doi. org/10. 1056/NEJMoa1404505.
2. Hawkes N. 2014. Ebola outbreak is a public health emergency of international concern, WHO warns. BMJ 349: g5089. http://dx. doi. org/10. 1136/bmj. g5089.
3. WHO Ebola Response Team. 2014. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med 371: 1481-1495 http://dx. doi. org/10. 1056/NEJMoa1411100.
4. Anonymous. 2014. Ethical considerations for use of unregistered interventions for Ebola virus disease (EVD). World Health Organization, Geneva, Switzerland.
5. Gulland A. 2014. First Ebola treatment is approved by WHO. BMJ 349: g5539. http://dx. doi. org/10. 1136/bmj. g5539.
6. Shuchman M. 2014. WHO enters new terrain in Ebola research. CMAJ 186: E527-E528 http://dx. doi. org/10. 1503/cmaj. 109-4893.
7. Sayburn A. 2014. WHO gives go ahead for experimental treatments to be used in Ebola outbreak. BMJ 349: g5161. http://dx. doi. org/10. 1136/bmj. g5161.
8. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I. 2010. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375: 1896-1905. http://dx. doi. org/10. 1016/S0140-6736(10)60357-1.
9. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S. 2010. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 16: 991-994. http://dx. doi. org/10. 1038/nm. 2202.
10. Qiu X, Audet J, Wong G, Fernando L, Bello A, Pillet S, Alimonti JB, Kobinger GP. 2013. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep 3: 3365. http://dx. doi. org/10. 1038/srep03365.
11. Pettitt J, Zeitlin L, Kim DH, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly MH, Whaley KJ, Ingram MF, Zovanyi A, Heinrich M, Piper A, Zelko J, Olinger GG. 2013. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 5: 199ra113. http://dx. doi. org/10. 1126/scitranslmed. 3006608.
12. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514: 47-53 http://dx. doi. org/10. 1038/nature13777.
13. Olinger GG, Jr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L. 2012. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A 109: 18030-18035. http://dx. doi. org/10. 1073/pnas. 1213709109.
14. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD. 2012. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 109: 5034-5039. http://dx. doi. org/10. 1073/pnas. 1200409109.
15. Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, Wong M, Smith WB, Vutikullird A, Kaye E. 2014. Safety and pharmacokinetic profiles of Phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: results of two singleascending dose studies. Antimicrob Agents Chemother 58: 6639-6647. http://dx. doi. org/10. 1128/AAC. 03442-14.
16. Kuhn JH, Andersen KG, Bào Y, Bavari S, Becker S, Bennett RS, Bergman NH, Blinkova O, Bradfute S, Brister JR, Bukreyev A, Chandran K, Chepurnov AA, Davey RA, Dietzgen RG, Doggett NA, Dolnik O, Dye JM, Enterlein S, Fenimore PW, Formenty P, Freiberg AN, Garry RF, Garza NL, Gire SK, Gonzalez JP, Griffiths A, Happi CT, Hensley LE, Herbert AS, Hevey MC, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson JC, Johnson KM, Kindrachuk J, Klenk HD, Kobinger G, Kochel TJ, Lackemeyer MG, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Omilabu SA, Palacios G, Panchal RG. 2014. Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names. Viruses 6: 3663-3682. http://dx. doi. org/10. 3390/v6093663.
17. Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Hensley LE, Honko AN, Jahrling PB, Johnson KM, Kobinger G, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Saphire EO, Smither SJ, Swanepoel R, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Weidmann M, Nichol ST. 2013. Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol 158: 301-311. http://dx. doi. org/10. 1007/s00705-012-1454-0.
18. Qiu X, Alimonti JB, Melito PL, Fernando L, Ströher U, Jones SM. 2011. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 141: 218-227. http://dx. doi. org/10. 1016/j. clim. 2011. 08. 008.
19. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287: 1664-1666. http://dx. doi. org/10. 1126/science. 287. 5458. 1664.
20. Stephen K, Gire AG, Andersen KG, Sealfon RSG, Park DJ, Kanneh L, Jalloh S, Momoh M, Fullah M, Dudas G, Wohl S, Moses LM, Yozwiak NL, Winnicki S, Matranga CB, Malboeuf CM, Qu J, Gladden AD, Schaffner SF, Yang X, Jiang P.-P, Nekoui M, Colubri A, Coomber RM, Fonnie M, Moigboi A, Gbakie M, Kamara FK, Tucker V, Konuwa E, Saffa S, Sellu J, Azziz Jalloh A, Kovoma A, Koninga J, Mustapha I, Kargbo K, Foday M, Yillah M, Kanneh F, Robert W, Massally JLB, Chapman SB, Bochicchio J, Murphy C, Nusbaum C, Young S, Birren BW, Grant DS, Scheiffelin JS, Lander ES, Happi C, Sahr M, Gnirke A, Rambaut A, Garry RF, Humarr Khan S, Pardis C, Sabeti PC. 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345: 1369-1372. http://dx. doi. org/10. 1126/science. 1259657.
21. Kuhn JH, Andersen KG, Baize S, Bào Y, Bavari S, Berthet N, Blinkova O, Brister JR, Clawson AN, Fair J, Gabriel M, Garry RF, Gire SK, Goba A, Gonzalez JP, Günther S, Happi CT, Jahrling PB, Kapetshi J, Kobinger G, Kugelman JR, Leroy EM, Maganga GD, Mbala PK, Moses LM, Muyembe-Tamfum JJ, N'Faly M, Nichol ST, Omilabu SA, Palacios G, Park DJ, Paweska JT, Radoshitzky SR, Rossi CA, Sabeti PC, Schieffelin JS, Schoepp RJ, Sealfon R, Swanepoel R, Towner JS, Wada J, Wauquier N, Yozwiak NL, Formenty P. 2014. Nomenclature-and databasecompatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses 6: 4760-4799. http://dx. doi. org/10. 3390/v6114760.
22. Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW, Nichol ST. 2005. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 332: 20-27. http://dx. doi. org/10. 1016/j. virol. 2004. 10. 048.
23. Swenson DL, Warfield KL, Warren TK, Lovejoy C, Hassinger JN, Ruthel G, Blouch RE, Moulton HM, Weller DD, Iversen PL, Bavari S. 2009. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother 53: 2089-2099. http://dx. doi. org/10. 1128/AAC. 00936-08.
24. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, MacLachlan I. 2006. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 193: 1650-1657. http://dx. doi. org/10. 1086/504267.